Effect of mepolizumab in eosinophilic chronic rhinosinusitis
Phase 2
Completed
- Conditions
- Chronic rhinosinusitisEosinophilic chronic rhinosinusitisRespiratory - Other respiratory disorders / diseases
- Registration Number
- ACTRN12618000113257
- Lead Sponsor
- Richard Harvey
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Adult patients with severe nasal polyp disease or eosinophilic chronic rhinosinusitis
Not currently receiving mepolizumab treatment
Patients who do not meet the PBS criteria for severe lower airway disease
Body weight: A minimum body weight >=40 kilograms (kg) at Visit 1
Gender: Male or female.
Informed consent: Capable of giving signed informed consent
Exclusion Criteria
Subjects with known hypersensitivity to mepolizumab
Subjects with other conditions that could lead to elevated eosinophils such as Hypereosinophilic Syndromes, including Churg-Strauss Syndrome, or Eosinophilic Esophagitis.
Subjects with known immunodeficiency
Subjects with cystic fibrosis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method